145 related articles for article (PubMed ID: 34387987)
1. Discovery of Soticlestat, a Potent and Selective Inhibitor for Cholesterol 24-Hydroxylase (CH24H).
Koike T; Yoshikawa M; Ando HK; Farnaby W; Nishi T; Watanabe E; Yano J; Miyamoto M; Kondo S; Ishii T; Kuroita T
J Med Chem; 2021 Aug; 64(16):12228-12244. PubMed ID: 34387987
[TBL] [Abstract][Full Text] [Related]
2. Discovery of Novel 3-Piperidinyl Pyridine Derivatives as Highly Potent and Selective Cholesterol 24-Hydroxylase (CH24H) Inhibitors.
Kajita Y; Ikeda S; Yoshikawa M; Fukuda H; Watanabe E; Yano J; Lane W; Miyamoto M; Ishii T; Nishi T; Koike T
J Med Chem; 2022 Feb; 65(4):3343-3358. PubMed ID: 35166541
[TBL] [Abstract][Full Text] [Related]
3. Design and synthesis of aryl-piperidine derivatives as potent and selective PET tracers for cholesterol 24-hydroxylase (CH24H).
Ikeda S; Kajita Y; Miyamoto M; Matsumiya K; Ishii T; Nishi T; Gay SC; Lane W; Constantinescu CC; Alagille D; Papin C; Tamagnan G; Kuroita T; Koike T
Eur J Med Chem; 2022 Oct; 240():114612. PubMed ID: 35863274
[TBL] [Abstract][Full Text] [Related]
4. Soticlestat, a novel cholesterol 24-hydroxylase inhibitor shows a therapeutic potential for neural hyperexcitation in mice.
Nishi T; Kondo S; Miyamoto M; Watanabe S; Hasegawa S; Kondo S; Yano J; Watanabe E; Ishi T; Yoshikawa M; Ando HK; Farnaby W; Fujimoto S; Sunahara E; Ohori M; During MJ; Kuroita T; Koike T
Sci Rep; 2020 Oct; 10(1):17081. PubMed ID: 33051477
[TBL] [Abstract][Full Text] [Related]
5. Preclinical characterization of [
Koike T; Constantinescu CC; Ikeda S; Nishi T; Sunahara E; Miyamoto M; Cole P; Barret O; Alagille D; Papin C; Morley T; Fowles K; Seibyl J; Tamagnan G; Kuroita T
Eur J Nucl Med Mol Imaging; 2022 Mar; 49(4):1148-1156. PubMed ID: 34651220
[TBL] [Abstract][Full Text] [Related]
6. Anticonvulsive properties of soticlestat, a novel cholesterol 24-hydroxylase inhibitor.
Nishi T; Metcalf CS; Fujimoto S; Hasegawa S; Miyamoto M; Sunahara E; Watanabe S; Kondo S; White HS
Epilepsia; 2022 Jun; 63(6):1580-1590. PubMed ID: 35316533
[TBL] [Abstract][Full Text] [Related]
7. Soticlestat, a novel cholesterol 24-hydroxylase inhibitor, reduces seizures and premature death in Dravet syndrome mice.
Hawkins NA; Jurado M; Thaxton TT; Duarte SE; Barse L; Tatsukawa T; Yamakawa K; Nishi T; Kondo S; Miyamoto M; Abrahams BS; During MJ; Kearney JA
Epilepsia; 2021 Nov; 62(11):2845-2857. PubMed ID: 34510432
[TBL] [Abstract][Full Text] [Related]
8. Population pharmacokinetics, enzyme occupancy, and 24S-hydroxycholesterol modeling of soticlestat, a novel cholesterol 24-hydroxylase inhibitor, in healthy adults.
Yin W; Facius A; Wagner T; Tsai M; Asgharnejad M; Lahu G; Vakilynejad M
Clin Transl Sci; 2023 Jul; 16(7):1149-1162. PubMed ID: 37212649
[TBL] [Abstract][Full Text] [Related]
9. Clinical Characterization of [
Constantinescu CC; Brown T; Wang S; Yin W; Barret O; Jennings D; Tauscher J
J Nucl Med; 2023 Dec; 64(12):1972-1979. PubMed ID: 37770111
[TBL] [Abstract][Full Text] [Related]
10. Cholesterol 24-hydroxylase is a novel pharmacological target for anti-ictogenic and disease modification effects in epilepsy.
Salamone A; Terrone G; Di Sapia R; Balosso S; Ravizza T; Beltrame L; Craparotta I; Mannarino L; Cominesi SR; Rizzi M; Pauletti A; Marchini S; Porcu L; Zimmer TS; Aronica E; During M; Abrahams B; Kondo S; Nishi T; Vezzani A
Neurobiol Dis; 2022 Oct; 173():105835. PubMed ID: 35932989
[TBL] [Abstract][Full Text] [Related]
11. The CH24H metabolite, 24HC, blocks viral entry by disrupting intracellular cholesterol homeostasis.
Yuan Y; Fang A; Wang Z; Wang Z; Sui B; Zhu Y; Zhang Y; Wang C; Zhang R; Zhou M; Chen H; Fu ZF; Zhao L
Redox Biol; 2023 Aug; 64():102769. PubMed ID: 37285742
[TBL] [Abstract][Full Text] [Related]
12. Characterization of soticlestat, a novel cholesterol 24-hydroxylase inhibitor, in acute and chronic neurodegeneration models.
Hasegawa S; Watanabe S; Fujimoto S; Kondo S; Nishi T
Neurosci Res; 2024 Jun; ():. PubMed ID: 38897234
[TBL] [Abstract][Full Text] [Related]
13. Population pharmacokinetics, enzyme occupancy, and pharmacodynamic modeling of soticlestat in patients with developmental and epileptic encephalopathies.
Yin W; Facius A; Asgharnejad M; Lahu G; Vakilynejad M
Clin Transl Sci; 2024 Mar; 17(3):e13722. PubMed ID: 38445548
[TBL] [Abstract][Full Text] [Related]
14. The antifungal drug voriconazole is an efficient inhibitor of brain cholesterol 24S-hydroxylase in vitro and in vivo.
Shafaati M; Mast N; Beck O; Nayef R; Heo GY; Björkhem-Bergman L; Lütjohann D; Björkhem I; Pikuleva IA
J Lipid Res; 2010 Feb; 51(2):318-23. PubMed ID: 19474457
[TBL] [Abstract][Full Text] [Related]
15. A phase 1b/2a study of soticlestat as adjunctive therapy in participants with developmental and/or epileptic encephalopathies.
Halford JJ; Sperling MR; Arkilo D; Asgharnejad M; Zinger C; Xu R; During M; French JA
Epilepsy Res; 2021 Aug; 174():106646. PubMed ID: 33940389
[TBL] [Abstract][Full Text] [Related]
16. The potential of CYP46A1 as a novel therapeutic target for neurological disorders: An updated review of mechanisms.
Alavi MS; Karimi G; Ghanimi HA; Roohbakhsh A
Eur J Pharmacol; 2023 Jun; 949():175726. PubMed ID: 37062503
[TBL] [Abstract][Full Text] [Related]
17. Safety, tolerability, pharmacokinetics, pharmacodynamics, bioavailability and food effect of single doses of soticlestat in healthy subjects.
Wang S; Chen G; Merlo Pich E; Affinito J; Cwik M; Faessel H
Br J Clin Pharmacol; 2021 Nov; 87(11):4354-4365. PubMed ID: 33837574
[TBL] [Abstract][Full Text] [Related]
18. Synthesis and pharmacokinetic study of a
Chen Z; Chen J; Mast N; Rong J; Deng X; Shao T; Fu H; Yu Q; Sun J; Shao Y; Josephson L; Collier TL; Pikuleva I; Liang SH
Bioorg Med Chem Lett; 2020 May; 30(9):127068. PubMed ID: 32178974
[TBL] [Abstract][Full Text] [Related]
19. Cholesterol 24-Hydroxylation by CYP46A1: Benefits of Modulation for Brain Diseases.
Petrov AM; Pikuleva IA
Neurotherapeutics; 2019 Jul; 16(3):635-648. PubMed ID: 31001737
[TBL] [Abstract][Full Text] [Related]
20. A phase 2, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of soticlestat as adjunctive therapy in pediatric patients with Dravet syndrome or Lennox-Gastaut syndrome (ELEKTRA).
Hahn CD; Jiang Y; Villanueva V; Zolnowska M; Arkilo D; Hsiao S; Asgharnejad M; Dlugos D
Epilepsia; 2022 Oct; 63(10):2671-2683. PubMed ID: 35841234
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
